FDA gives Saniona candidate priority status

The US FDA has given biotech firm Saniona's drug candidate Tesomet priority status as an orphan drug for treating hypothalamic obesity. Earlier this year, Tesomet received the same priority status as a treatment for Prader-Willi syndrome.

Photo: Andrew Kelly/REUTERS / X02844

The US Food and Drug Administration FDA has given orphan drug priority status to Saniona's drug candidate Tesomet for treating hypothalamic obesity (HO), according to a press release on Monday.

"There are currently no FDA-approved medicines for hypothalamic obesity. Despite the devastating weight gain and hunger this rare disease can cause, there has been relatively little drug development specifically for HO," says Saniona Chief Medical Officer and Head of Clinical Development Rudolf Baumgartner in the press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs